MEP11109A - High affinity human antibodies to human il-4 receptor - Google Patents

High affinity human antibodies to human il-4 receptor

Info

Publication number: MEP11109A
Authority: ME; Montenegro
Prior art keywords: human; receptor; high affinity; antibodies; human antibodies
Prior art date: 2006-10-02

Application number

MEP-111/09A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Sean Stevens

Tammy T Huang

Joel H Martin

Jeanett E L Fairhurst

Ashique Rafique

Marcela Torres

Kevin J Pobursky

Raymond W Leidich

Joan A Windsor

Warren R Mikulka

Diana M Ahrens

Ergang Shi

Nicholas J Papadopoulos

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-02

Filing date

2007-10-02

Publication date

2011-12-20

2007-10-02 Application filed filed Critical

2011-12-20 Publication of ME00616B publication Critical patent/ME00616B/me

2011-12-20 Publication of MEP11109A publication Critical patent/MEP11109A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Urology & Nephrology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Mycology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Plant Pathology (AREA)

MEP-111/09A 2006-10-02 2007-10-02 High affinity human antibodies to human il-4 receptor MEP11109A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US84869406P	2006-10-02	2006-10-02
US95773807P	2007-08-24	2007-08-24
PCT/US2007/021210 WO2008054606A2 (en)	2006-10-02	2007-10-02	High affinity human antibodies to human il-4 receptor

Publications (2)

Publication Number	Publication Date
ME00616B ME00616B (me)	2011-12-20
MEP11109A true MEP11109A (en)	2011-12-20

Family

ID=39344836

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-111/09A MEP11109A (en)	2006-10-02	2007-10-02	High affinity human antibodies to human il-4 receptor

Country Status (34)

Country	Link
US (4)	US7605237B2 (xx)
EP (3)	EP2069403B1 (xx)
JP (1)	JP2010505418A (xx)
KR (1)	KR101474227B1 (xx)
CN (1)	CN101522716B (xx)
AU (1)	AU2007314522C9 (xx)
BR (1)	BRPI0719953B8 (xx)
CA (1)	CA2664343C (xx)
CO (1)	CO6160305A2 (xx)
CR (1)	CR10689A (xx)
CY (1)	CY1115551T1 (xx)
DK (2)	DK2069403T3 (xx)
DO (1)	DOP2009000058A (xx)
ES (2)	ES2466669T3 (xx)
HR (2)	HRP20140512T1 (xx)
HU (1)	HUE054090T2 (xx)
IL (1)	IL197479A (xx)
LT (1)	LT2769992T (xx)
MA (1)	MA31138B1 (xx)
ME (1)	MEP11109A (xx)
MX (1)	MX2009003393A (xx)
MY (1)	MY149079A (xx)
NI (1)	NI200900041A (xx)
NO (1)	NO347180B1 (xx)
NZ (1)	NZ576040A (xx)
PL (2)	PL2069403T3 (xx)
PT (2)	PT2069403E (xx)
RS (2)	RS53340B (xx)
RU (1)	RU2445318C2 (xx)
SI (2)	SI2069403T1 (xx)
TN (1)	TN2009000110A1 (xx)
UA (1)	UA98943C2 (xx)
WO (1)	WO2008054606A2 (xx)
ZA (1)	ZA200901617B (xx)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050144655A1 (en)	2000-10-31	2005-06-30	Economides Aris N.	Methods of modifying eukaryotic cells
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
PT1523496E (pt)	2002-07-18	2011-09-29	Merus B V	Produção de misturas de anticorpos de forma recombinante
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
EP1639009B1 (en)	2003-05-30	2013-02-27	Merus B.V.	Fab library for the preparation of a mixture of antibodies
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
CA2708871C (en) *	2007-12-21	2017-11-21	Medimmune Limited	Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CN102123582B (zh)	2008-06-27	2015-09-30	莫鲁斯有限公司	产生抗体的非人哺乳动物
US8871207B2 (en)	2008-07-25	2014-10-28	Humabs, LLC	Neutralizing anti-influenza A virus antibodies and uses thereof
RU2553325C2 (ru)	2008-07-25	2015-06-10	Институт Фо Ресёч Ин Биомедицин	Нейтрализующие антитела против вируса гриппа а и их использование
AU2014216019B2 (en) *	2008-10-29	2016-04-21	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to Human IL-4 receptor
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
NO2792236T3 (xx) *	2009-07-08	2018-04-14
US9445581B2 (en)	2012-03-28	2016-09-20	Kymab Limited	Animal models and therapeutic molecules
US9796788B2 (en)	2010-02-08	2017-10-24	Regeneron Pharmaceuticals, Inc.	Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en)	2010-02-08	2013-02-21	Regeneron Pharmaceuticals, Inc.	Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL3095871T3 (pl)	2010-02-08	2019-10-31	Regeneron Pharma	Mysz zawierająca wspólny łańcuch lekki
ME02902B (me)	2010-06-22	2018-04-20	Regeneron Pharma	Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
RS55495B1 (sr)	2010-08-02	2017-04-28	Regeneron Pharma	Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
PH12013500672A1 (en)	2010-10-06	2013-06-03	Regeneron Pharma	Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies
DK2714738T3 (en)	2011-05-24	2019-01-28	Zyngenia Inc	MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
CN102830228B (zh) *	2011-06-15	2015-01-21	格诺思博生物科技(上海)有限公司	定量分析循环肿瘤细胞的试剂及试剂盒
AR087329A1 (es) *	2011-06-17	2014-03-19	Regeneron Pharma	Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN107915775B (zh)	2011-07-11	2022-07-12	伊克诺斯科学公司	结合ox40的抗体及其用途
ES2841899T3 (es)	2011-07-18	2021-07-12	Inst Res Biomedicine	Anticuerpos neutralizantes del virus de la influenza A y usos de los mismos
IL273982B2 (en)	2011-08-05	2023-03-01	Regeneron Pharma	Humanized mice possess a universal light chain
ES2773111T3 (es)	2011-09-16	2020-07-09	Regeneron Pharma	Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
EP2758535B1 (en)	2011-09-19	2016-11-09	Kymab Limited	Antibodies, variable domains&chains tailored for human use
EP2761008A1 (en)	2011-09-26	2014-08-06	Kymab Limited	Chimaeric surrogate light chains (slc) comprising human vpreb
CA2791109C (en)	2011-09-26	2021-02-16	Merus B.V.	Generation of binding molecules
US9253965B2 (en) *	2012-03-28	2016-02-09	Kymab Limited	Animal models and therapeutic molecules
BR112014015238B1 (pt)	2011-12-20	2022-11-16	Regeneron Pharmaceuticals, Inc	Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
EP3539374A1 (en)	2012-03-16	2019-09-18	Regeneron Pharmaceuticals, Inc.	Non-human animals expressing ph-sensitive immunoglobulin sequences
CN106318951A (zh)	2012-03-16	2017-01-11	瑞泽恩制药公司	生产具有ph依赖性结合特性的抗原结合蛋白的小鼠
LT2883449T (lt)	2012-03-16	2018-05-10	Regeneron Pharmaceuticals, Inc.	Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
US20140013456A1 (en)	2012-03-16	2014-01-09	Regeneron Pharmaceuticals, Inc.	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en)	2012-03-28	2019-04-09	Kymab Limited	Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en)	2012-05-17	2013-11-20	Kymab Ltd	Multivalent antibodies and in vivo methods for their production
ES2740749T3 (es)	2012-04-20	2020-02-06	Merus Nv	Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
PT3470432T (pt)	2012-08-21	2021-12-14	Regeneron Pharma	Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r
BR112015005048A8 (pt)	2012-09-07	2018-01-30	Regeneron Pharma	métodos para tratar dermatite atópica por administração de antagonista il-4r
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
EP2840892B1 (en) *	2013-02-20	2018-04-18	Regeneron Pharmaceuticals, Inc.	Non-human animals with modified immunoglobulin heavy chain sequences
EP3521312B1 (en)	2013-02-20	2021-04-07	Innate Pharma	A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
EA201890895A1 (ru)	2013-03-15	2019-02-28	Зинджения, Инк.	Мультивалентные и моновалентные мультиспецифические комплексы и их применение
US9788534B2 (en)	2013-03-18	2017-10-17	Kymab Limited	Animal models and therapeutic molecules
US9783618B2 (en)	2013-05-01	2017-10-10	Kymab Limited	Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en)	2013-05-02	2017-10-10	Kymab Limited	Antibodies, variable domains and chains tailored for human use
US11707056B2 (en)	2013-05-02	2023-07-25	Kymab Limited	Animals, repertoires and methods
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI697334B (zh)	2013-06-04	2020-07-01	美商再生元醫藥公司	藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) *	2013-06-21	2021-11-03	사노피 바이오테크놀로지	Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh)	2013-07-11	2020-01-21	美商再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
SG11201602236SA (en)	2013-10-01	2016-04-28	Kymab Ltd	Animal models and therapeutic molecules
DK3052192T3 (da)	2013-10-02	2020-09-28	Medimmune Llc	Neutraliserende anti-influenza a-antistoffer og anvendelser deraf
DE202014010499U1 (de)	2013-12-17	2015-10-20	Kymab Limited	Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US20170065702A1 (en) *	2014-02-19	2017-03-09	Cangene Corporation	Methods of modulating an immune response
IL315136A (en)	2014-02-21	2024-10-01	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4rantagonist
JP6526037B2 (ja)	2014-02-28	2019-06-05	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法
JP6636498B2 (ja)	2014-03-21	2020-01-29	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	単一ドメイン結合タンパク質を作る非ヒト動物
RU2016141123A (ru)	2014-03-21	2018-04-23	Регенерон Фармасьютикалз, Инк.	Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
CA2954780A1 (en)	2014-07-15	2016-01-21	Medimmune, Llc	Neutralizing anti-influenza b antibodies and uses thereof
WO2016023916A1 (en)	2014-08-12	2016-02-18	Kymab Limited	Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en)	2014-11-07	2016-05-12	Kymab Limited	Treatment of disease using ligand binding to targets of interest
EP3218412A1 (en)	2014-11-14	2017-09-20	Sanofi Biotechnology	Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
CA2978902A1 (en) *	2015-03-06	2016-09-15	Sorrento Therapeutics, Inc.	Antibody therapeutics that bind jag1
US11111314B2 (en)	2015-03-19	2021-09-07	Regeneron Pharmaceuticals, Inc.	Non-human animals that select for light chain variable regions that bind antigen
EP3277725B1 (en)	2015-03-30	2020-11-25	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to fc gamma receptors
HK1250514A1 (zh)	2015-04-02	2018-12-21	Intervet International B.V.	针对犬白介素-4受体α的抗体
SMT202100591T1 (it)	2015-06-01	2021-11-12	Medimmune Llc	Molecole di legame anti-influenza neutralizzanti e loro usi
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
TWI797060B (zh) *	2015-08-04	2023-04-01	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
CN106939047B (zh)	2016-01-04	2021-08-31	江苏怀瑜药业有限公司	一种pd-l1抗体及其制备方法
AU2017207330C1 (en)	2016-01-13	2022-06-09	Medimmune, Llc	Method of treating influenza A
AU2017220184B2 (en)	2016-02-19	2024-04-18	Regeneron Pharmaceuticals, Inc.	Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
CN113372446A (zh) *	2016-06-08	2021-09-10	苏州康乃德生物医药有限公司	用于结合白细胞介素4受体的抗体
CA3035202A1 (en)	2016-09-01	2018-03-08	Regeneron Pharmaceuticals, Inc.	Methods for preventing or treating allergy by administering an il-4r antagonist
CA3037499A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
WO2018075378A1 (en) *	2016-10-17	2018-04-26	Vanderbilt University	Human respiratory syncytial virus antibodies and methods of use therefor
TWI857389B (zh)	2016-12-01	2024-10-01	美商再生元醫藥公司	治療發炎症狀的方法
CN110234348B (zh)	2016-12-16	2024-06-25	蓝鳍生物医药公司	抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
WO2018190990A1 (en)	2017-04-13	2018-10-18	Regeneron Pharmaceuticals, Inc.	Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
CN107216388B (zh) *	2017-08-07	2020-05-05	广州泰诺迪生物科技有限公司	一种治疗丙型肝炎病毒药物的制备方法和用途
PT3515465T (pt)	2017-08-18	2024-03-04	Regeneron Pharma	Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
CA3079946A1 (en)	2017-10-30	2019-05-09	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4r antagonist
CN108373505B (zh) *	2018-04-20	2019-08-20	北京智仁美博生物科技有限公司	抗il-4r抗体及其用途
JP2021523188A (ja)	2018-05-13	2021-09-02	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法
CN113101364B (zh)	2018-05-29	2023-12-01	康诺亚生物医药科技（成都）有限公司	一种自免疫抑制剂的开发和应用
FI3823443T3 (fi) *	2018-07-16	2024-07-25	Regeneron Pharma	Ditra-taudin jyrsijämallit ja niiden käyttö
EP3808774B1 (en)	2018-08-24	2025-04-16	Jiangsu Hengrui Medicine Co., Ltd.	Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
EP3878868B1 (en) *	2018-11-09	2024-10-09	Ajou University Industry-Academic Cooperation Foundation	Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN111494625B (zh) *	2018-12-25	2022-06-21	江苏荃信生物医药股份有限公司	用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
CN113677707A (zh)	2019-03-06	2021-11-19	瑞泽恩制药公司	用于在治疗癌症中增强效力的il-4/il-13途径抑制剂
CN121102493A (zh)	2019-03-21	2025-12-12	瑞泽恩制药公司	用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CN113795262A (zh) *	2019-04-08	2021-12-14	东莞凡恩世生物医药有限公司	人源化抗dll3嵌合抗原受体及其用途
CN112010977B (zh)	2019-05-29	2022-04-26	山东博安生物技术股份有限公司	抗白介素4受体(il-4r)的抗体及其应用
CA3147436A1 (en)	2019-07-16	2021-01-21	Sanofi Biotechnology	Methods for treating or preventing asthma by administering an il-4r antagonist
CN112279914A (zh) *	2019-07-25	2021-01-29	苏州丁孚靶点生物技术有限公司	Il4ra抗体、基因、载体、宿主细胞和il4ra拮抗剂
WO2021026203A1 (en)	2019-08-05	2021-02-11	Regeneron Pharmaceuticals, Inc.	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
MX2022001247A (es)	2019-08-05	2022-04-25	Regeneron Pharma	Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
CA3161037A1 (en)	2019-12-09	2021-06-17	Sanofi Biotechnology	Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en)	2020-11-02	2022-05-04	Sanofi Biotechnology	Methods for treating digitally-identified il-4/il-13 related disorders
WO2021167952A2 (en) *	2020-02-20	2021-08-26	The Feinstein Institutes For Medical Research	Agonist antibodies against endoglin and uses thereof
BR112022016345A2 (pt)	2020-02-21	2022-12-20	Jiangsu Hengrui Pharmaceuticals Co Ltd	Composição farmacêutica contendo anticorpo anti-il-4r e uso da mesma
CA3169479A1 (en) *	2020-02-27	2021-09-02	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Antibodies binding il4r and uses thereof
EP4126951A1 (en)	2020-03-27	2023-02-08	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4132658A4 (en) *	2020-04-10	2024-08-21	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	Binders and chimeric antigen receptors specific for interleukin-1 receptor accessory protein
CN113527485B (zh)	2020-04-17	2024-11-15	湖南麦济生物技术股份有限公司	抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) *	2020-04-24	2021-10-26	苏州康乃德生物医药有限公司	与人IL-4Rα中特定表位结合的抗体及其应用
BR112022022235A2 (pt)	2020-05-22	2023-03-28	Regeneron Pharma	Métodos para tratamento de esofagite eosinofílica através da administração de inibidor de il-4r
CN116348605A (zh)	2020-07-17	2023-06-27	Gi 医诺微新	包含IgE Fc受体α亚基胞外结构域和抗IL-4R抗体的融合蛋白及其应用
KR102697769B1 (ko)	2020-09-14	2024-08-23	아주대학교산학협력단	인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도
JP2023544406A (ja)	2020-10-05	2023-10-23	サノフィ・バイオテクノロジー	Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法
JP2023554557A (ja)	2020-12-22	2023-12-27	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	抗ｉｌ－４ｒ抗体又はその抗原結合断片の複合物及び医薬用途
US12065505B2 (en)	2021-01-08	2024-08-20	Bristol-Myers Squibb Company	Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof
KR20230130681A (ko)	2021-01-08	2023-09-12	리제너론 파아마슈티컬스, 인크.	Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
WO2023009437A1 (en)	2021-07-26	2023-02-02	Sanofi Biotechnology	Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TWI876192B (zh) *	2021-08-05	2025-03-11	美商美國禮來大藥廠	人類介白素-4受體α抗體
EP4392450A1 (en)	2021-08-23	2024-07-03	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
CN117615785A (zh) *	2021-08-26	2024-02-27	正大天晴药业集团股份有限公司	抗il4r抗体的药物组合物及其用途
EP4419557A1 (en)	2021-10-20	2024-08-28	Sanofi Biotechnology	Methods for treating prurigo nodularis by administering an il-4r antagonist
WO2023130010A1 (en)	2021-12-30	2023-07-06	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
KR20240134329A (ko)	2022-01-29	2024-09-09	상하이 쉥디 파마슈티컬 컴퍼니 리미티드	글루코코르티코이드의 약물 접합체
CN119053625A (zh)	2022-03-02	2024-11-29	瑞泽恩制药公司	用于抗体生产的细胞培养方法
WO2023215750A2 (en)	2022-05-02	2023-11-09	Regeneron Pharmaceuticals, Inc.	Methods for reducing lipase activity
US20240024472A1 (en)	2022-05-02	2024-01-25	Regeneron Pharmaceuticals, Inc.	Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations
US20240034798A1 (en)	2022-07-08	2024-02-01	Regeneron Pharmaceuticals, Inc.	Methods for treating eosinophilic esophagitis by administering an il-4r antagonist
EP4580659A1 (en)	2022-08-29	2025-07-09	Sanofi Biotechnology	Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
KR20250096792A (ko)	2022-11-01	2025-06-27	리제너론 파아마슈티컬스, 인크.	Il-4r 길항제를 투여하여 손 및 발 피부염을 치료하기 위한 방법
WO2024112935A1 (en)	2022-11-23	2024-05-30	Regeneron Pharmaceuticals, Inc.	Methods for improving bone growth by administering an il-4r antagonist
TW202502819A (zh)	2023-03-22	2025-01-16	法商賽諾菲生物技術公司	藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
CN121001741A (zh)	2023-03-27	2025-11-21	瑞泽恩制药公司	用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
AR134008A1 (es)	2023-10-02	2025-11-26	Regeneron Pharma	Sistema de seguridad de dispositivo de administración de fármaco
WO2025096932A1 (en)	2023-11-02	2025-05-08	Regeneron Pharmaceuticals, Inc.	Methods for reducing lipase activity using stress
WO2025137344A1 (en)	2023-12-20	2025-06-26	Bristol-Myers Squibb Company	Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2025221640A1 (en)	2024-04-15	2025-10-23	Sanofi Biotechnology	Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US809A (en)		1838-06-27		Improved mode of changing the poles of electro-magnets
US7186A (en)		1850-03-19		fetchec
GB8808015D0 (en)	1988-04-06	1988-05-05	Ritter M A	Chemical compounds
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
WO1990005183A1 (en)	1988-10-31	1990-05-17	Immunex Corporation	Interleukin-4 receptors
NZ255101A (en)	1992-07-24	1997-08-22	Cell Genesys Inc	A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5714146A (en)	1992-08-26	1998-02-03	Board Of Regents Of The University Of Washington	IL-4 bone therapy
EP0604693A1 (en) *	1992-12-29	1994-07-06	Schering-Plough	Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) *	1993-09-07	2001-02-10	Смитклайн Бичам Корпорейшн	Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1283851B1 (en)	2000-05-26	2012-03-28	Immunex Corporation	Use of il-4r antibodies and compositions thereof
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
WO2003048083A2 (en) *	2001-11-30	2003-06-12	Biogen Idec Ma Inc.	Antibodies against monocyte chemotactic proteins
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
UA93653C2 (ru)	2003-11-07	2011-03-10	Иммунекс Корпорейшн	Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
AU2004309373A1 (en) *	2003-12-22	2005-07-14	Amgen Inc.	Methods for identifying functional antibodies
WO2005085284A1 (en)	2004-02-27	2005-09-15	Regeneron Pharmaceuticals, Inc.	Il-4/il-13 sepecific polypetides and therapeutic uses thereof
US20090098142A1 (en)	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) *	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
TWI306862B (en) *	2005-01-03	2009-03-01	Hoffmann La Roche	Antibodies against il-13 receptor alpha 1 and uses thereof
US7608693B2 (en)	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor

2007
- 2007-10-02 MX MX2009003393A patent/MX2009003393A/es active IP Right Grant
- 2007-10-02 CN CN200780036872.1A patent/CN101522716B/zh active Active
- 2007-10-02 WO PCT/US2007/021210 patent/WO2008054606A2/en not_active Ceased
- 2007-10-02 EP EP07867197.1A patent/EP2069403B1/en active Active
- 2007-10-02 EP EP20207210.4A patent/EP3845563A3/en active Pending
- 2007-10-02 RU RU2009116608/10A patent/RU2445318C2/ru active
- 2007-10-02 PT PT78671971T patent/PT2069403E/pt unknown
- 2007-10-02 PL PL07867197T patent/PL2069403T3/pl unknown
- 2007-10-02 NZ NZ576040A patent/NZ576040A/en unknown
- 2007-10-02 ES ES07867197.1T patent/ES2466669T3/es active Active
- 2007-10-02 UA UAA200904256A patent/UA98943C2/ru unknown
- 2007-10-02 CA CA2664343A patent/CA2664343C/en active Active
- 2007-10-02 HU HUE14162081A patent/HUE054090T2/hu unknown
- 2007-10-02 PL PL14162081T patent/PL2769992T3/pl unknown
- 2007-10-02 ES ES14162081T patent/ES2859825T3/es active Active
- 2007-10-02 DK DK07867197.1T patent/DK2069403T3/da active
- 2007-10-02 RS RS20140308A patent/RS53340B/sr unknown
- 2007-10-02 PT PT141620815T patent/PT2769992T/pt unknown
- 2007-10-02 US US11/906,517 patent/US7605237B2/en active Active
- 2007-10-02 EP EP14162081.5A patent/EP2769992B1/en active Active
- 2007-10-02 AU AU2007314522A patent/AU2007314522C9/en active Active
- 2007-10-02 KR KR1020097008844A patent/KR101474227B1/ko active Active
- 2007-10-02 SI SI200731493T patent/SI2069403T1/sl unknown
- 2007-10-02 RS RS20210392A patent/RS61650B1/sr unknown
- 2007-10-02 MY MYPI20091180A patent/MY149079A/en unknown
- 2007-10-02 BR BRPI0719953A patent/BRPI0719953B8/pt active IP Right Grant
- 2007-10-02 SI SI200732172T patent/SI2769992T1/sl unknown
- 2007-10-02 HR HRP20140512TT patent/HRP20140512T1/hr unknown
- 2007-10-02 DK DK14162081.5T patent/DK2769992T3/da active
- 2007-10-02 JP JP2009531433A patent/JP2010505418A/ja active Pending
- 2007-10-02 LT LTEP14162081.5T patent/LT2769992T/lt unknown
- 2007-10-02 ME MEP-111/09A patent/MEP11109A/xx unknown
- 2007-10-02 NO NO20091758A patent/NO347180B1/no unknown
2009
- 2009-03-06 ZA ZA2009/01617A patent/ZA200901617B/en unknown
- 2009-03-08 IL IL197479A patent/IL197479A/en active IP Right Grant
- 2009-03-24 CR CR10689A patent/CR10689A/es unknown
- 2009-03-30 NI NI200900041A patent/NI200900041A/es unknown
- 2009-03-31 TN TN2009000110A patent/TN2009000110A1/fr unknown
- 2009-04-01 DO DO2009000058A patent/DOP2009000058A/es unknown
- 2009-04-30 MA MA31835A patent/MA31138B1/fr unknown
- 2009-04-30 CO CO09044043A patent/CO6160305A2/es unknown
- 2009-09-04 US US12/554,029 patent/US7794717B2/en active Active
2010
- 2010-06-23 US US12/821,499 patent/US8092802B2/en active Active
2011
- 2011-12-02 US US13/309,594 patent/US8338135B2/en active Active
2014
- 2014-08-07 CY CY20141100620T patent/CY1115551T1/el unknown
2021
- 2021-03-10 HR HRP20210408TT patent/HRP20210408T1/hr unknown

Also Published As

Publication number	Publication date
CN101522716B (zh)	2013-03-20
DOP2009000058A (es)	2009-04-30
HK1200846A1 (en)	2015-08-14
HUE054090T2 (hu)	2021-08-30
AU2007314522C9 (en)	2013-08-01
US7794717B2 (en)	2010-09-14
MX2009003393A (es)	2009-05-11
AU2007314522C1 (en)	2013-06-27
CA2664343A1 (en)	2008-05-08
WO2008054606A2 (en)	2008-05-08
CR10689A (es)	2009-06-24
IL197479A (en)	2014-03-31
LT2769992T (lt)	2021-04-12
EP2069403B1 (en)	2014-05-07
AU2007314522A2 (en)	2009-07-02
KR101474227B1 (ko)	2014-12-18
PL2069403T3 (pl)	2015-08-31
IL197479A0 (en)	2011-08-01
AU2007314522B2 (en)	2013-02-21
BRPI0719953A2 (pt)	2014-04-29
US20100291107A1 (en)	2010-11-18
MA31138B1 (fr)	2010-02-01
PL2769992T3 (pl)	2021-08-02
US8092802B2 (en)	2012-01-10
CA2664343C (en)	2016-04-26
KR20090088865A (ko)	2009-08-20
NO20091758L (no)	2009-05-04
EP2769992B1 (en)	2020-12-30
NZ576040A (en)	2011-06-30
ES2466669T3 (es)	2014-06-10
CN101522716A (zh)	2009-09-02
EP3845563A3 (en)	2021-11-24
SI2069403T1 (sl)	2014-09-30
RS61650B1 (sr)	2021-04-29
PT2069403E (pt)	2014-07-18
PT2769992T (pt)	2021-03-11
RU2445318C2 (ru)	2012-03-20
ES2859825T3 (es)	2021-10-04
BRPI0719953B8 (pt)	2021-05-25
US20080160035A1 (en)	2008-07-03
HK1131790A1 (en)	2010-02-05
ME00616B (me)	2011-12-20
SI2769992T1 (sl)	2021-04-30
EP2769992A3 (en)	2015-01-21
US8338135B2 (en)	2012-12-25
MY149079A (en)	2013-07-15
WO2008054606A3 (en)	2009-02-05
AU2007314522A8 (en)	2013-04-11
AU2007314522B8 (en)	2013-04-11
CO6160305A2 (es)	2010-05-20
HRP20210408T1 (hr)	2021-04-30
EP2769992A2 (en)	2014-08-27
UA98943C2 (ru)	2012-07-10
RS53340B (sr)	2014-10-31
RU2009116608A (ru)	2010-11-10
EP3845563A2 (en)	2021-07-07
ZA200901617B (en)	2009-12-30
NI200900041A (es)	2011-10-17
US20120135010A1 (en)	2012-05-31
HRP20140512T1 (hr)	2014-07-04
EP2069403A2 (en)	2009-06-17
DK2769992T3 (da)	2021-03-22
NO347180B1 (no)	2023-06-19
US20100021476A1 (en)	2010-01-28
CY1115551T1 (el)	2017-01-04
BRPI0719953B1 (pt)	2019-04-24
AU2007314522A1 (en)	2008-05-08
US7605237B2 (en)	2009-10-20
TN2009000110A1 (en)	2010-08-19
JP2010505418A (ja)	2010-02-25
DK2069403T3 (da)	2014-07-28

Publication	Publication Date	Title
MEP11109A (en)	2011-12-20	High affinity human antibodies to human il-4 receptor
SV2009003296A (es)	2009-10-27	Anticuerpos humanos contra el ligando 4 de tipo delta humano
CY1122092T1 (el)	2020-07-31	Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4
NZ590816A (en)	2013-02-22	Anti-il-12/il-23 antibodies
CY1112456T1 (el)	2015-12-09	Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
ATE484749T1 (de)	2010-10-15	Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung
BRPI0607692A2 (pt)	2009-09-22	peptìdeos para detecção de anticorpo para o vìrus da sìndrome reprodutiva e respiratória suìna
ATE468535T1 (de)	2010-06-15	Verwendung von nnmt als marker für lungenkrebs
UA103624C2 (ru)	2013-11-11	Антитело, мишенью которого является полипептид baffr
WO2010022924A8 (en)	2010-12-09	Antibodies against human epo receptor
HN2009000575A (es)	2011-11-23	Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
TN2011000133A1 (en)	2012-09-05	High affinity human antibodies to human il-4 receptor
TH95346A (th)	2009-04-30	แอนตี้-fgf 19 แอนตี้บอดี้และวิธีการใช้สิ่งเหล่านี้